Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope you won't hold it against me.
Yes. When they get a partnership deal this will explode.
They're in the middle of either raising funds or working on a partnership deal. That's why they haven't released any news.
Nobody should be. It's a roll of the dice.
I'm not sold on the value of their drug candidates. They still don't have patents for their 2 drug candidates and they still have to make the EB drug which takes about a year plus another 6 months to prove shelf life. I'm also suspicious why we haven't heard a word on their glaucoma patent.
The reason I bought this stock is for the potential value of the bioinformatics and biosynthesis they're touting. They're way behind Nemus in drug development and Nemus has 1/4 the outstanding shares. That's why I own both.
It hasn't been shelved at all. They just announced they contracted out to manufacture the drug to FDA standards. They're very confident it's more effective than anything on the market. They just think the other drug can get approval faster because its similar to what the FDA has already approved.
Thank you for the info. I think their chemo side effect drug will be first since they have made the drug to FDA standards and they think they can fast tack it.
It all comes down to what InMed really has. If they have something they'll be able to raise money at the current price per share. If it's still looked upon as a more speculative company then the raise will come in at the price levels before the pump. I don't think paid pumps are very ethical but it has helped get retail attention.
They pumped just before the raise. You can't do any press releases during a raise.
They're in the middle of raising capital and/or working on development deals so they can't issue any press releases until that's done. They're following SEC rules right now.
The phone number is for the PR company but it used to be the Nemus office phone. The PR company rep will answer questions for you. I haven't been in contact for a couple months but I've spoken to Murphy and the CFO a few times over the past couple years.
$250k was announced 2 years ago when he joined. The day to day I heard from the current CEO.
The only ones who sold were the shell guys from Miami who got 3 million shares in the deal and drove the price down. They're gone. The rest of the price drop is related to being unknown and they don't pump. Hard to believe Nemus has the lowest market cap than every other company on the sector with the most valuable IP. Management is working on something. Just have to be patient.
Ingram also put in $250k and is actively involved in the day to day operations.
So InMed has what they call Bioinformatics and so does Revive. Both say it's very valuable. Who has the better IP or do they collaborate? Is Bioinformatics something other companies are doing and just don't promote it or do these 2 Canadian companies have the market cornered?
http://www.revivethera.com/bioinformatics.html
I have no idea how shorting works on OTC stocks or how it's even done. With low volume and a very narrow trading range, I doubt there's much money to be made. I think the Market Makers are just trading back and forth to cover their positions.
There's no news because Nemus is working on financing/development deals so they can't do any press during that. Unlike other companies who put out the same news over and over and pay to pump the price.
Since the beginning. As far as cannabinoid drugs go, I don't think there's another company that comes close to what Nemus has in the pipeline. It just comes down to being able to execute a partnership deal with good terms.
Lapham was one of the founders of the company who helped establish the relationship with Misssippi and helped put management together before it went public. He advises from time to time but is smart enough to know Nemus needed great management with a proven track record.
The Mississippi doctors do get paid for their research but their payday only comes when revenue is generated or there's a buyout. You can imagine how much IP they developed over the years and had many parthenerhsip offers but they believed in the Nemus guys to move this along and to be able to monetize it.
Maybe you can answer this please. In May 2015, they announced they filed patents for EB and glaucoma. No provisional patent numbers were ever provided. Why did they announce they filed a patent for EB again in 2017? How come their annual information form makes no mention of a pending glaucoma patent? Have they filed a patent for their biosynthesis process?
You sure have changed your tune in 2 months. I'm just not convinced yet. Hoping for the best but I don't like the pumping they've done.
Nope. Wasn't me.
Good post. Do you think there will be any obstacles to getting FDA approval if the cream is extracted from the plant and not synthetic?
They've already formulated their chemo side effect drug to FDA standards and have another month or two to go to show it has the required 2 year shelf life. They'll be able to fast track that drug and they released other news like their Staph drug worked that went ignored. Since there has been no news of late, I assume that means they're in the middle of raising funds or negotiating a development deal since they can't do any press during that process.
I took a shot and bought this before the paid pump so it's been good from that stand point. I think I posted earlier that it looks like they did it because it was the same recycled story from various sources. I'm sure management looks at it like it helps them negotiate a better price when they're raising private money but it concerns me. The SEC is starting to take a closer look at this type of promotion and it violates SEC rules to do any type of press release when a company is in the middle of a raise. InMed just raised money to last a while so hopefully they're not out raising money now because it's a violation.
This type of thing makes me nervous because it pumps up the stock based on awareness and not necessarily the IP. The releases tell a good story but it's not like it's anything concrete like results from a Phase III study. It's just the company touting things we can't verify yet. They still only have pending patents and it looks to me like they announced filing for a patent for EB in 2015 and then again recently which makes me wonder. Why'd they announce it 2 years apart and why did they only include a pending patent number this time? Are they 2 different patents? When did the clock start on this patent filing? 2015 or 2017?
As far as their biosynthesis process goes, it concerns me that on every press release they state that everyone is using the plant to make their drugs when that's not true. Zynerba, Nemus and others are using synthetics. Perhaps InMed has a better biosynthesis process than Teewinot and others but it's a total unknown and InMed is not the only game in town as implied.
Bioinformatics? Sounds good but who knows? Bottom line is this is a very speculative stock and they may have something with their biosynthesis and bioinformatics that will pay off in the shorter term. Their 2 drug candidates may have value too but they are well behind others in drug development.
I'm hanging on to this for now but I get nervous when I see paid pumps and board pumpers who tout this as a $1 billion company this early in the game.
Whether they change scheduling is probably irrelevant. FDA approved drugs will be cheaper, the only ones doctors prescribe and will be covered by insurance. The approved drugs will most likely be synthetic too.
The type of drugs being developed to go through the FDA process will be. And they'll be tested whereas everything else will not be considered to meet FDA standards.
I have my concerns that Sessions is going to make an example out of some people in a few states. Longer term, as soon as pharma starts getting FDA approval for various drugs that doctors can then describe for anything they want at their discretion, virtually all the non-FDA approved drugs are going to go away. The reason being is FDA drugs will be cheaper, covered by insurance and prescribed by doctors for liability reasons.
Any company not seeking to get FDA approved drugs in the long term are risking being left out.
As far as saying marijuana is a harmless drug is completey untrue. All you have to do is google studies that show there are those at risk for psychotic reactions if they are genetically predisposed. That's part of the reason why most companies are staying away from drugs taken orally. It's little known but there were a couple of companies who stopped Phase III clinical trials 20 years ago because of the psychoactive effects. I believe one of them was Valeant.
You get it. And the IP is the most valuable of anyone in the sector. That's fact. No bs.
Good luck. If they can execute funding, this thing will be worth more than every company in the sector. Their IP is that good.
Thank you for your input. I'm in on both.
Do you think Murphy and Ingram would put anything fake out? It's all legit. They're too under the radar.
In December, the CEO stated that 18 months was the soonest trials would start. I've seen no updates saying they're still on track or that they can make their drug or if the patents have been approved.
Nemus isn't using the plant and are way more transparent than what InMed puts out and I own both.
Clinical trials are 18 months to 2 years out unless the company adjusts their timeline.
The former CEO has been gone almost 2 years. He just wasn't the guy to move them forward long term and not needed with Ingram and Murphy.
As far as the stock price goes, it's a mystery to me. They don't pump the stock at all and their priority is to move the science along not put out puff pieces. They've proven they can make their leading drug candidate and I don't think people realize what a big deal that is because it's not cheap or easy to do. And it will be fast tracked through the FDA because it's so similar to what's already approved. They've known for years their glaucoma and Staph drugs work and have announced scientific results. What they have is legit. They just don't care about marketing to the retail investor. It's about the science and negotiating potential partnerships.
Their market cap is the lowest of all stocks in the sector. Even the ones that are complete fraud. They've had much higher offers for their IP alone but passed because it's much more valuable,
Just clarifiying thst it can only be sold and manufactured in the legal states.
Certainly could be. But only after it gets FDA approval.
Any of your examples considered Schedule I drugs? Hasn't management already said they're only selling in the legal states?
Their press release today didn't say anything. They've put a lot of the same info out for the past few weeks so this could just be part of their plan to keep the name out there. They don't have patents yet on their 2 candidates. I have no idea if they have patents on their biosynthesis or bioinformatics but that's what appears to me to be driving the stock. The hope is that it's really as good as they say they are and that's what I took a chance on.
I know for a fact that the process that makes Nemus' lead drug does it cheaply and quickly. And it's been proven. No idea if InMed has a better process but they have competition which you'd never guess from their press.
The former Nemus CEO was an Amgen guy who filled a need when they first went public, Once they added the quality people on their board, especially Ingram, then they no longer needed him. It made sense to save the money.
Nemus showed they can make their chemo side effect drug to FDA standards a few months ago. That takes at least a year and then it takes another 6 months to show it can have a 2 year shelf life. They've started to do the same thing for their glaucoma drug. Now InMed has no drug patents yet that they say were filed 2 years ago so and if they get them tomorrow, they're 18 months to 2 years out from doing the same.
I have no idea who Zynerba is using to make their synthetic drugs but I doubt they're using some antiquated process. The point I'm making is InMed continuously touts that others are using the plant and it's disingenuous. And their drug PR's are repeats from the last 2 years. The rumor is they spent $15k for a PR campaign which I'm beginning to believe based on the amount of annoucnemts and today's recycled release. But again, I'm taking a shot here in case they do have something.
They've been touting this stuff for 3 years. Maybe bioinformatics has value but nobody has been banging on their door in 3 years and others are using Teewinot and others to make their synthetics so it's not like nobody is doing biosynthesis like InMed intimates. I hope they're valuable but they've shown me nothing concrete yet. Their drug candidates have been essentially stalled for 2 years. But I like their management so I'm in.
If you want to see a no bs press release, look at the one Nemus released regarding Staph infections. Proof their drug candidate works. The university has known it and tested it for years and now Nemus is formally proving it. That alone would be worth billions. Now let's see if they can get a partner on it and their other candidates.